NASDAQ:SYRS Syros Pharmaceuticals Q1 2024 Earnings Report $0.03 -0.01 (-17.31%) As of 04/25/2025 03:57 PM Eastern Earnings HistoryForecast Syros Pharmaceuticals EPS ResultsActual EPS-$0.79Consensus EPS -$0.89Beat/MissBeat by +$0.10One Year Ago EPS-$0.85Syros Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.30 millionBeat/MissN/AYoY Revenue GrowthN/ASyros Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/14/2024TimeBefore Market OpensConference Call DateTuesday, May 14, 2024Conference Call Time8:30AM ETConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Syros Pharmaceuticals Q1 2024 Earnings Call TranscriptProvided by QuartrMay 14, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Good morning, and welcome to Syrah's Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. This call is being webcast live on the Investors and Media section of Sirus' website at www.sirus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Cara Uniti, Director of Investor Relations and Corporate Communications at Cerus. Speaker 100:00:34Thank you. This morning, we issued a press release announcing our Q1 2024 financial results. The full release is available on the Investor and Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Conley Chi, our Chief Executive Officer Doctor. David Roth, our Chief Medical Officer and Jason Haas, our Chief Financial Officer. Speaker 100:01:02We will then open the call for questions. Kristen Stephens, our Chief Development Officer, is also on the call and will be available for Q and A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward looking statements. Actual events or results could differ materially than those expressed or implied by any forward looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our quarterly report on Form 10 Q that we filed this morning, our annual Any forward looking statements represent our views only as of today, Any forward looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward looking statements. Speaker 100:02:02I would now like to turn the call over to Conley. Conley? Speaker 200:02:06Thanks, Karen, and thank you everyone for joining this morning. 2024 marks an important year for Syros. We're acutely focused on execution across our clinical development programs and pre commercial activities as we continue to advance tamibarotene, a potential new standard of care for the frontline treatment of hematologic malignancies. We are very encouraged by recent progress of our programs in higher risk MDS and unfit AML. As David will discuss shortly, our Phase III Select MDS I trial recently passed a pre specified interim futility analysis. Speaker 200:02:46This is a meaningful milestone for our program. The interim futility analysis was designed to evaluate the primary endpoint of complete response. And as a reminder, we remain blinded to the data that was reviewed by the independent data monitoring committee. They recommended that our study continue without modification and while that result was anticipated, this is an important step to pass as we look forward to reporting our pivotal data by mid Q4 of this year. Also in April, the FDA granted fast track designation for tamibaracine in combination with venetoclax and azacitidine for the treatment of newly diagnosed unfit AML with RARA overexpression. Speaker 200:03:28As you know, Fast Track designation is granted to compounds that are intended to treat serious conditions and for which non clinical or clinical data demonstrated the potential to address unmet medical needs. We believe that this designation not only reflects the need for a new therapeutic option in AML, it speaks to the strength of our initial data from select AML1, which we reported at the end of last year. This is the 2nd FDA fast track designation that we received for tamivarotene. Previously, the FDA granted this designation to tamivarotene in combination with azacitidine for the treatment of higher risk MDS with RANRA overexpression. Together, the progress that I described continues to reinforce our confidence in the potential for tamivarotene to provide a safe and efficacious therapy for MDS and AML patients with RARA overexpression. Speaker 200:04:26We look forward to important data readouts ahead, including additional data from our Phase II Select AML1 trial expected in Q3 of this year. And as I mentioned before, pivotal data from our Phase 3 select MDS1 trial expected by mid Q4. As we approach these readouts, I'm also really pleased by our progress in advancing our launch readiness activities, so we can effectively deliver tamivarotene to patients in the U. S. Following approval. Speaker 200:04:58We look forward to sharing details of our launch preparations as we move closer to a potential NDA filing. With that, I'll now turn it over to David to review our programs and upcoming milestones in more detail. David? Speaker 300:05:13Thank you, Conley. We're excited with the continued progress in advancing tamiferatin through late stage development. As we announced in March, we completed enrollment of the 190 patients necessary to support the complete response rate primary endpoint analysis. And we remain on track to report pivotal CR data by the middle of Q4 of this year. And as Conley mentioned, we are highly encouraged by the recently completed pre specified select MDS1 interim futility analysis, which was conducted by an independent data monitoring committee, who recommended that the trial continue without modification. Speaker 300:05:56The analysis looked at CR data across the two arms of the trial, data that remains blinded to Syros and it passed. In addition, no concerning safety signals were noted. This is a meaningful milestone, particularly in the higher risk MDS setting, where passing a futility analysis in a pivotal registration trial cannot be taken for granted. Over the past several years, the competitive landscape in higher risk MDS has become narrower and narrower as compounds have failed interim futility analyses or primary analyses for reasons related to efficacy and or safety. This encouraging outcome based on an evaluation of half of the enrolled patients needed for our primary analysis underscores the potential for tamubarotene to provide profound benefit to patients and we look forward to pivotal data later this year. Speaker 300:06:51As a reminder, the ongoing SELECT MDS-one trial is a randomized double blind placebo controlled trial evaluating the combination of tamubarotene and azacitidine versus placebo and azacitidine in newly diagnosed higher risk MDS patients with RARA overexpression. The existing standard of care for higher risk MDS patients provides limited efficacy with a 17% complete response rate and a median overall survival of just 18.6 months. No new therapies beyond hypomethylating agents have been approved in newly diagnosed higher risk MDS in well over a decade, which provides the opportunity for our biologically targeted approach with tambouratin to improve the care and treatment of patients with RARA overexpression, who can be readily identified using a simple blood test. To date, studies of tamibarotene have demonstrated a generally well tolerated safety profile, which is particularly important in patients with higher risk MDS, who are commonly elderly and with underlying comorbidities that preclude intensive treatment options. To provide additional perspective on our higher risk MDS program, we will be hosting a webcast event on June 25th to discuss MDS disease biology and the current treatment landscape in higher risk MDS as well as the design of the ongoing pivotal Phase 3 select MDS I trial and the opportunity for tami barite. Speaker 300:08:25We're excited to have medical experts and disease specialists join Syros to discuss and present on these topics. Now turning to AML, we continue to advance tamubarotene in the randomized select AML1 Phase 2 clinical trial in unfit AML patients with RARA overexpression. In April, we were pleased to announce the FDA decision to grant fast track designation for tamubarotene in combination with venetoclax and azacitidine for the treatment of newly diagnosed unfit AML patients with rawogene overexpression as detected by an FDA approved test. This designation reflects the tremendous need for a safe and effective therapy for AML patients, many of whom are unable to tolerate intensive treatment. We are especially encouraged that this designation was given based on an FDA review that included the initial interim data from a pre specified analysis of the randomized portion of the select ANNO-one study in which we saw encouraging CR and CRCRI rates in the triplet with tamubarotene compared to the standard of care. Speaker 300:09:37These results were also bolstered by safety data that demonstrated no additive toxicity. Overall, the data continue to support the potential for tannubarotene in combination with standard of care in the frontline treatment of AML patients with RARA overexpression. We also believe these results in AML increase our confidence in the ongoing evaluation of tamivarotene in combination with azacitidine in higher risk MDS. Based on data to date, we believe samibarotene is uniquely positioned to improve upon the standard of care in higher risk MDS and in AML. And we look forward to reporting clinical activity and tolerability data from a pre specified analysis of over 40 patients from the randomized portion of the select AML1 trial in the Q3 of this year and the pivotal data readout from the Phase 3 select MDS1 trial by the middle of Q4 of this year. Speaker 300:10:37I would now like to turn the call over to Jason, our Chief Financial Officer, to review our Q1 financial results. Jason? Speaker 400:10:46Thank you, David. Now I'll turn to our Q1 financial results. We did not recognize any revenue in the Q1 of 2024 as compared to $3,000,000 for the Q1 of 2023. The decrease reflects the termination of Syros' collaboration agreement with Pfizer late last year. R and D expenses were $24,700,000 this quarter compared to $28,800,000 for the Q1 of 2023. Speaker 400:11:12The decrease was primarily due to the reduction in external R and D consulting, contract manufacturing and a reduction in headcount and related expenses. Speaker 200:11:20Our R and Speaker 400:11:21D expenditures are now principally focused on the advancement of tamivarotene. G and A expenses were $6,300,000 in the Q1 of 2024 as compared to $7,400,000 in the same quarter last year. The decrease was primarily due to a reduction in headcount and related expenses, consulting and facilities expenses. We reported a net loss for the Q1 of $3,700,000 or $0.10 per share compared to a net loss of $23,800,000 or $0.85 per share for the same period in 20 23. Cash, cash equivalents and marketable securities as of March 31, 2024 were $108,300,000 as compared with $139,500,000 on December 31, 2023. Speaker 400:12:07On May 9, we agreed to amend our loan agreement with Oxford. The amendment will provide us with more financial flexibility by extending the interest only period from September 1, 2024 to November 1, 2025 with further extensions to as late as November 1, 2026 upon the achievement of certain milestones. In addition, the amendment will allow us to increase the amount of term loans available to us from $40,000,000 to $100,000,000 with 2 tranches totaling $40,000,000 becoming available upon the achievement of certain milestones and an additional $20,000,000 becoming available at Oxford's discretion. With the Oxford Amendment, which extends our interest only period to November 2025, we believe our current cash position will be sufficient to fund our anticipated operating expenses and capital expenditure requirements into the Q3 of 2025 beyond pivotal Phase 3 data from the select MDS1 trial and additional data from the randomized portion of the select AML1 trial. With that, I will turn the call over to the operator for questions. Operator00:13:14We will now begin the question and answer Your first question comes from the line of Phil Nadeau from TD Cowen. Your line is open. Speaker 500:13:44Good morning. Congrats on the progress. Thanks for taking our questions. 2 from us. First on the interim analysis in select MDS-one, I think you said the analysis looked at 50% of the patients who will be involved in the primary endpoint. Speaker 500:14:00Is that correct? And could you give us any additional information on the statistical bar for the futility analysis? And then second question in AML, do you think you'll have enough information post that Q3 update to make a gono go decision on pivotal development Speaker 300:14:26questions. So the interim you did hear correctly, the interim analysis was a pre specified futility analysis. And the futility analysis was triggered based on when 50% of the patients who are going to be contributing to the final primary analysis had a sufficient time on study. The data were reviewed in a blinded fashion by an independent data monitoring committee. They looked at the complete response rates across the two arms. Speaker 300:14:56We remain blinded to that information. So we have no information specifically about what those results showed. However, we were told that we passed and we were also told that there were no new safety signals or anything of concern and that we should continue the trial without any modification. So of course, we were very excited about that. We haven't specifically shared the details on the statistical bars that one had to achieve. Speaker 300:15:23I just think it's an important point to be to take home that it's very encouraging that we passed and it's an important and requisite milestone to achieve such that we can now look forward to reporting the final data on the primary endpoint in by the middle of Q4 of this year. So that's exciting. And then with regard to your AML question, at this point, we're anticipating reporting out another pre specified analysis from that study in the Q3. That will be based on including at least 40 of the patients. So that will be at least half the trial will have outcomes. Speaker 300:16:08And I think it would be important to realize that without having seen the data, the actual analysis that we're going to be sharing hasn't been seen yet. It's hard to project when we would have a go, no go. And that's the kind of thing where we could provide you with an update in the future. Speaker 500:16:28That's very helpful. Thanks for taking our questions. Operator00:16:42There are no further questions at this time. I will turn the call to Collie Chi for giving closing remarks. Speaker 200:16:50Great. Thanks, operator, and thanks, everyone, for joining us today and for your continued support of Syros. Please reach out to the team if you have further questions. Have a great day. Operator00:17:02Ladies and gentlemen, thank you for participating. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallSyros Pharmaceuticals Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Syros Pharmaceuticals Earnings HeadlinesSyros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.comApril 22, 2025 | americanbankingnews.comRege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.April 27, 2025 | Stansberry Research (Ad)Syros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSee More Syros Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Syros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syros Pharmaceuticals and other key companies, straight to your email. Email Address About Syros PharmaceuticalsSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.View Syros Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Good morning, and welcome to Syrah's Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. This call is being webcast live on the Investors and Media section of Sirus' website at www.sirus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Cara Uniti, Director of Investor Relations and Corporate Communications at Cerus. Speaker 100:00:34Thank you. This morning, we issued a press release announcing our Q1 2024 financial results. The full release is available on the Investor and Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Conley Chi, our Chief Executive Officer Doctor. David Roth, our Chief Medical Officer and Jason Haas, our Chief Financial Officer. Speaker 100:01:02We will then open the call for questions. Kristen Stephens, our Chief Development Officer, is also on the call and will be available for Q and A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward looking statements. Actual events or results could differ materially than those expressed or implied by any forward looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our quarterly report on Form 10 Q that we filed this morning, our annual Any forward looking statements represent our views only as of today, Any forward looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward looking statements. Speaker 100:02:02I would now like to turn the call over to Conley. Conley? Speaker 200:02:06Thanks, Karen, and thank you everyone for joining this morning. 2024 marks an important year for Syros. We're acutely focused on execution across our clinical development programs and pre commercial activities as we continue to advance tamibarotene, a potential new standard of care for the frontline treatment of hematologic malignancies. We are very encouraged by recent progress of our programs in higher risk MDS and unfit AML. As David will discuss shortly, our Phase III Select MDS I trial recently passed a pre specified interim futility analysis. Speaker 200:02:46This is a meaningful milestone for our program. The interim futility analysis was designed to evaluate the primary endpoint of complete response. And as a reminder, we remain blinded to the data that was reviewed by the independent data monitoring committee. They recommended that our study continue without modification and while that result was anticipated, this is an important step to pass as we look forward to reporting our pivotal data by mid Q4 of this year. Also in April, the FDA granted fast track designation for tamibaracine in combination with venetoclax and azacitidine for the treatment of newly diagnosed unfit AML with RARA overexpression. Speaker 200:03:28As you know, Fast Track designation is granted to compounds that are intended to treat serious conditions and for which non clinical or clinical data demonstrated the potential to address unmet medical needs. We believe that this designation not only reflects the need for a new therapeutic option in AML, it speaks to the strength of our initial data from select AML1, which we reported at the end of last year. This is the 2nd FDA fast track designation that we received for tamivarotene. Previously, the FDA granted this designation to tamivarotene in combination with azacitidine for the treatment of higher risk MDS with RANRA overexpression. Together, the progress that I described continues to reinforce our confidence in the potential for tamivarotene to provide a safe and efficacious therapy for MDS and AML patients with RARA overexpression. Speaker 200:04:26We look forward to important data readouts ahead, including additional data from our Phase II Select AML1 trial expected in Q3 of this year. And as I mentioned before, pivotal data from our Phase 3 select MDS1 trial expected by mid Q4. As we approach these readouts, I'm also really pleased by our progress in advancing our launch readiness activities, so we can effectively deliver tamivarotene to patients in the U. S. Following approval. Speaker 200:04:58We look forward to sharing details of our launch preparations as we move closer to a potential NDA filing. With that, I'll now turn it over to David to review our programs and upcoming milestones in more detail. David? Speaker 300:05:13Thank you, Conley. We're excited with the continued progress in advancing tamiferatin through late stage development. As we announced in March, we completed enrollment of the 190 patients necessary to support the complete response rate primary endpoint analysis. And we remain on track to report pivotal CR data by the middle of Q4 of this year. And as Conley mentioned, we are highly encouraged by the recently completed pre specified select MDS1 interim futility analysis, which was conducted by an independent data monitoring committee, who recommended that the trial continue without modification. Speaker 300:05:56The analysis looked at CR data across the two arms of the trial, data that remains blinded to Syros and it passed. In addition, no concerning safety signals were noted. This is a meaningful milestone, particularly in the higher risk MDS setting, where passing a futility analysis in a pivotal registration trial cannot be taken for granted. Over the past several years, the competitive landscape in higher risk MDS has become narrower and narrower as compounds have failed interim futility analyses or primary analyses for reasons related to efficacy and or safety. This encouraging outcome based on an evaluation of half of the enrolled patients needed for our primary analysis underscores the potential for tamubarotene to provide profound benefit to patients and we look forward to pivotal data later this year. Speaker 300:06:51As a reminder, the ongoing SELECT MDS-one trial is a randomized double blind placebo controlled trial evaluating the combination of tamubarotene and azacitidine versus placebo and azacitidine in newly diagnosed higher risk MDS patients with RARA overexpression. The existing standard of care for higher risk MDS patients provides limited efficacy with a 17% complete response rate and a median overall survival of just 18.6 months. No new therapies beyond hypomethylating agents have been approved in newly diagnosed higher risk MDS in well over a decade, which provides the opportunity for our biologically targeted approach with tambouratin to improve the care and treatment of patients with RARA overexpression, who can be readily identified using a simple blood test. To date, studies of tamibarotene have demonstrated a generally well tolerated safety profile, which is particularly important in patients with higher risk MDS, who are commonly elderly and with underlying comorbidities that preclude intensive treatment options. To provide additional perspective on our higher risk MDS program, we will be hosting a webcast event on June 25th to discuss MDS disease biology and the current treatment landscape in higher risk MDS as well as the design of the ongoing pivotal Phase 3 select MDS I trial and the opportunity for tami barite. Speaker 300:08:25We're excited to have medical experts and disease specialists join Syros to discuss and present on these topics. Now turning to AML, we continue to advance tamubarotene in the randomized select AML1 Phase 2 clinical trial in unfit AML patients with RARA overexpression. In April, we were pleased to announce the FDA decision to grant fast track designation for tamubarotene in combination with venetoclax and azacitidine for the treatment of newly diagnosed unfit AML patients with rawogene overexpression as detected by an FDA approved test. This designation reflects the tremendous need for a safe and effective therapy for AML patients, many of whom are unable to tolerate intensive treatment. We are especially encouraged that this designation was given based on an FDA review that included the initial interim data from a pre specified analysis of the randomized portion of the select ANNO-one study in which we saw encouraging CR and CRCRI rates in the triplet with tamubarotene compared to the standard of care. Speaker 300:09:37These results were also bolstered by safety data that demonstrated no additive toxicity. Overall, the data continue to support the potential for tannubarotene in combination with standard of care in the frontline treatment of AML patients with RARA overexpression. We also believe these results in AML increase our confidence in the ongoing evaluation of tamivarotene in combination with azacitidine in higher risk MDS. Based on data to date, we believe samibarotene is uniquely positioned to improve upon the standard of care in higher risk MDS and in AML. And we look forward to reporting clinical activity and tolerability data from a pre specified analysis of over 40 patients from the randomized portion of the select AML1 trial in the Q3 of this year and the pivotal data readout from the Phase 3 select MDS1 trial by the middle of Q4 of this year. Speaker 300:10:37I would now like to turn the call over to Jason, our Chief Financial Officer, to review our Q1 financial results. Jason? Speaker 400:10:46Thank you, David. Now I'll turn to our Q1 financial results. We did not recognize any revenue in the Q1 of 2024 as compared to $3,000,000 for the Q1 of 2023. The decrease reflects the termination of Syros' collaboration agreement with Pfizer late last year. R and D expenses were $24,700,000 this quarter compared to $28,800,000 for the Q1 of 2023. Speaker 400:11:12The decrease was primarily due to the reduction in external R and D consulting, contract manufacturing and a reduction in headcount and related expenses. Speaker 200:11:20Our R and Speaker 400:11:21D expenditures are now principally focused on the advancement of tamivarotene. G and A expenses were $6,300,000 in the Q1 of 2024 as compared to $7,400,000 in the same quarter last year. The decrease was primarily due to a reduction in headcount and related expenses, consulting and facilities expenses. We reported a net loss for the Q1 of $3,700,000 or $0.10 per share compared to a net loss of $23,800,000 or $0.85 per share for the same period in 20 23. Cash, cash equivalents and marketable securities as of March 31, 2024 were $108,300,000 as compared with $139,500,000 on December 31, 2023. Speaker 400:12:07On May 9, we agreed to amend our loan agreement with Oxford. The amendment will provide us with more financial flexibility by extending the interest only period from September 1, 2024 to November 1, 2025 with further extensions to as late as November 1, 2026 upon the achievement of certain milestones. In addition, the amendment will allow us to increase the amount of term loans available to us from $40,000,000 to $100,000,000 with 2 tranches totaling $40,000,000 becoming available upon the achievement of certain milestones and an additional $20,000,000 becoming available at Oxford's discretion. With the Oxford Amendment, which extends our interest only period to November 2025, we believe our current cash position will be sufficient to fund our anticipated operating expenses and capital expenditure requirements into the Q3 of 2025 beyond pivotal Phase 3 data from the select MDS1 trial and additional data from the randomized portion of the select AML1 trial. With that, I will turn the call over to the operator for questions. Operator00:13:14We will now begin the question and answer Your first question comes from the line of Phil Nadeau from TD Cowen. Your line is open. Speaker 500:13:44Good morning. Congrats on the progress. Thanks for taking our questions. 2 from us. First on the interim analysis in select MDS-one, I think you said the analysis looked at 50% of the patients who will be involved in the primary endpoint. Speaker 500:14:00Is that correct? And could you give us any additional information on the statistical bar for the futility analysis? And then second question in AML, do you think you'll have enough information post that Q3 update to make a gono go decision on pivotal development Speaker 300:14:26questions. So the interim you did hear correctly, the interim analysis was a pre specified futility analysis. And the futility analysis was triggered based on when 50% of the patients who are going to be contributing to the final primary analysis had a sufficient time on study. The data were reviewed in a blinded fashion by an independent data monitoring committee. They looked at the complete response rates across the two arms. Speaker 300:14:56We remain blinded to that information. So we have no information specifically about what those results showed. However, we were told that we passed and we were also told that there were no new safety signals or anything of concern and that we should continue the trial without any modification. So of course, we were very excited about that. We haven't specifically shared the details on the statistical bars that one had to achieve. Speaker 300:15:23I just think it's an important point to be to take home that it's very encouraging that we passed and it's an important and requisite milestone to achieve such that we can now look forward to reporting the final data on the primary endpoint in by the middle of Q4 of this year. So that's exciting. And then with regard to your AML question, at this point, we're anticipating reporting out another pre specified analysis from that study in the Q3. That will be based on including at least 40 of the patients. So that will be at least half the trial will have outcomes. Speaker 300:16:08And I think it would be important to realize that without having seen the data, the actual analysis that we're going to be sharing hasn't been seen yet. It's hard to project when we would have a go, no go. And that's the kind of thing where we could provide you with an update in the future. Speaker 500:16:28That's very helpful. Thanks for taking our questions. Operator00:16:42There are no further questions at this time. I will turn the call to Collie Chi for giving closing remarks. Speaker 200:16:50Great. Thanks, operator, and thanks, everyone, for joining us today and for your continued support of Syros. Please reach out to the team if you have further questions. Have a great day. Operator00:17:02Ladies and gentlemen, thank you for participating. You may now disconnect.Read morePowered by